a 192

A 192 is a biochemical.

MI-192 is a selective HDAC2 and HDAC3 inhibitor with IC50 values of 30 nM and 16 nM, respectively. It exhibits greater selectivity for HDAC2/3 over other HDAC isomers and induces apoptosis in myeloid leukemic cells, indicating potential therapeutic use in leukemia and as an anti-stroke agent [1] [2].

AGH-192, an efficient agonist with compound-like properties, may serve as an ideal tool compound for studying 5-HT7 receptor functions. Furthermore, its observed analgesic effects in a murine neuropathic pain model indicate its potential as a pain-relieving medication.

Antitumor agent-192 (Compound 2f) is a β-carboline antitumor compound. It induces autophagy in HCT116 cells via the ATG5/ATG7 pathway. The IC50 of Antitumor agent-192 against human tumor cell lines is below 5 μM, and it significantly inhibits tumor growth and reduces tumor weight in xenograft mouse models of colorectal cancer.

Anticanceragent 192 (compound XXI) is a steroid-based histamine H3 receptor antagonist with no affinity for muscarinic and hERG receptors. It shows considerable stability in human and rat liver microsomes. Additionally, in addiction tests conducted on rats, Anticanceragent 192 enhances cognitive levels and reduces addiction severity.

DGY-09-192 is a PROTAC FGFR1/2 degrader with DC50 values of 4.35 nM for FGFR1 and 70 nM for FGFR2. It selectively degrades wild-type FGFR1/2 and various FGFR2 fusion proteins, including FGFR2-PHGDH and FGFR2-OPTN. In both in vitro and in vivo studies, DGY-09-192 inhibits downstream FGFR signaling pathways by reducing the phosphorylation of FRS2Y196 and ERK1/2T202/Y204.

CRBN ligand-192 is an E3 ligase ligand used in the synthesis of PROTACs, such as [PROTACBRD4 Degrader-41]. [PROTACBRD4 Degrader-41] is a potent BRD4 PROTAC degrader with anti-cancer properties.

Tyrosinase (192-200), a human mouse nonapeptide, is recognizable by cytolytic T cells (CTL) on the HLA-B44 molecule and is utilized in the research of melanoma-associated cancers [1].

YLT192 is an orally active and bioavailable VEGFR2 inhibitor. It also has potent antiangiogenic activity and antitumor efficacy.

LBX192( NVP-LBX192) is a liver-targeted glucokinase activator.

ML192 (CID1434953) is a selective GPR55 ligand antagonist. ML192 is an inhibitor that inhibits β-arrestin transport, ERK1/2 phosphorylation, and PKCβII translocation.

TAT-PAK18 R192A is an inactive Tat-Pak peptide. It does not influence Rac1 translocation triggered by any tested proteins.

A-192621 is a potent, nonpeptide, orally active, and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and elevates both arterial blood pressure and plasma ET-1 levels[1][2][3]. Its selectivity is 636-fold higher for ETB than ETA (IC50 of 4280 nM and Ki of 5600 nM).

Anti-Mesothelin Antibody (YP218) is a chimeric rabbit IgG antibody that targets human Mesothelin.

PMN310 is a monoclonal antibody targeting β-amyloid oligomers (AβO). It prevents AβO-induced memory formation loss in vivo and reduces synaptic loss and inflammation. PMN310 is applicable in Alzheimer's disease research.

Selcodebart is a humanized IgG1κ monoclonal antibody inhibitor targeting the repulsive guidance molecule C (RGMC/HFE2) and exhibits anti-anemic properties. Abdakibart is applicable to research on central nervous system disorders, such as Alzheimer's disease and stroke, as well as brain tumors and anemia.

Lenipagrusin alfa is a natural homologous tetramer variant of Sophora japonica seed lectin (1-258), in its glycosylated form as alfa. Lenipagrusin alfa exhibits antitumor properties.

BIW-8962 is a humanized anti-ganglioside GM2 antibody demonstrating ADCC/CDC activity against multiple myeloma cells. In murine xenograft models, BIW-8962 exhibits potent antitumor activity. This compound is applicable for research on cancers such as myeloma.

Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. It is applicable in research related to inflammatory diseases, such as idiopathic pulmonary fibrosis (IPF).

REGN7999 is a monoclonal antibody that inhibits TMPRSS6. By suppressing TMPRSS6 activity, REGN7999 prevents HJV cleavage, enhancing BMP6-HJV signaling and increasing serum hepcidin levels. This inhibition aids in alleviating iron overload and impaired erythropoiesis in β-thalassemia mouse models. REGN7999 is applicable for research in β-thalassemia.

Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal inhibitory antibody targeting human and monkey CD16a, which can be used in immunological research.

Anti-Human/Mouse/Monkey PD-1 Antibody (2E5) is a monoclonal inhibitory antibody targeting PD-1. PD-1 is a cell membrane receptor mainly expressed on the surface of T cells and pre-B cells. Binding of PD-1 to its ligands PD-L1 and PD-L2 reduces the body’s immune response by inhibiting T cell activation. Therefore, PD-1 serves as a key immune checkpoint and an important target for the development of targeted antibody drugs for various malignant tumors.

Anti-Human CD62L Antibody (DREG-200) is a monoclonal inhibitory antibody targeting human CD62L, applicable to immunology research.

Anti-Human CD86 Antibody (3D1) is a monoclonal inhibitory antibody targeting human CD86, which can be used in immunology research.